Management of Frail Older Adults with Newly Diagnosed Multiple Myeloma — Moving Toward a Personalized Approach

Siegel, 2020, Cancer statistics, 2020, Ca-a Cancer Journal for Clinicians, 70, 7, 10.3322/caac.21590

Cowan, 2018, Global Burden of Multiple Myeloma ASystematic Analysis for the Global Burden of Disease Study 2016, Jama Oncology, 4, 1221, 10.1001/jamaoncol.2018.2128

Krok-Schoen, 2018, Incidence and survival of hematological cancers among adults ages >= 75years, Cancer Medicine, 7, 3425, 10.1002/cam4.1461

Kumar, 2019, Trends in Early Mortality from Multiple Myeloma (MM): A Population-Based Analysis, Blood, 134, 71, 10.1182/blood-2019-124799

Engelhardt, 2020, Structured assessment of frailty in multiple myeloma as a paradigm of individualized treatment algorithms in cancer patients at advanced age, Haematologica, 10.3324/haematol.2019.242958

Palumbo, 2015, Geriatric assessment predicts survival and toxicities in elderly myeloma patients: an International Myeloma Working Group report, Blood, 125, 2068, 10.1182/blood-2014-12-615187

Engelhardt, 2017, A concise revised Myeloma Comorbidity Index as a valid prognostic instrument in a large cohort of 801 multiple myeloma patients, Haematologica, 102, 910, 10.3324/haematol.2016.162693

Schutz, 2017, Frailty and mortality in elderly patients with multiple myeloma, Haematologica, 102, 518

Milani, 2016, N-terminal fragment of the type-B natriuretic peptide (NT-proBNP) contributes to a simple new frailty score in patients with newly diagnosed multiple myeloma, American Journal of Hematology, 91, 1129, 10.1002/ajh.24532

Facon, 2020, A simplified frailty scale predicts outcomes in transplant-ineligible patients with newly diagnosed multiple myeloma treated in the FIRST (MM-020) trial, Leukemia, 34, 224, 10.1038/s41375-019-0539-0

Cook, 2019, A clinical prediction model for outcome and therapy delivery in transplant-ineligible patients with myeloma (UK Myeloma Research Alliance Risk Profile): a development and validation study, Lancet Haematology, 6, E154, 10.1016/S2352-3026(18)30220-5

Nathwani, 2020, Integrating Touchscreen-Based Geriatric Assessment and Frailty Screening for Adults With Multiple Myeloma to Drive Personalized Treatment Decisions, Jco Oncology Practice, 16, 39-+, 10.1200/JOP.19.00208

Mohile, 2018, Practical Assessment and Management of Vulnerabilities in Older Patients Receiving Chemotherapy: ASCO Guideline for Geriatric Oncology, Journal of Clinical Oncology, 36, 10.1200/JCO.2018.78.8687

Larocca, 2018, Patient-centered practice in elderly myeloma patients: an overview and consensus from the European Myeloma Network (EMN), Leukemia, 32, 1697, 10.1038/s41375-018-0142-9

Wildiers, 2014, International Society of Geriatric Oncology Consensus on Geriatric Assessment in Older Patients With Cancer, Journal of Clinical Oncology, 32, 2595, 10.1200/JCO.2013.54.8347

Zweegman, 2017, Hematology. Elderly patients with multiple myeloma: towards a frailty approach?, Current Opinion in Oncology, 29, 315, 10.1097/CCO.0000000000000395

Rockwood, 2004, Prevalence, attributes, and outcomes of fitness and frailty in community-dwelling older adults: Report from the Canadian Study of Health and Aging, Journals of Gerontology Series a-Biological Sciences and Medical Sciences, 59, 1310, 10.1093/gerona/59.12.1310

Larocca, 2018, Efficacy and Feasibility of Dose/Schedule-Adjusted Rd-R Vs. Continuous Rd in Elderly and Intermediate-Fit Newly Diagnosed Multiple Myeloma (NDMM) Patients: RV-MM-PI-0752 Phase III Randomized Study, Blood, 132

Mikhael, 2019, Treatment of Multiple Myeloma: ASCO and CCO Joint Clinical Practice Guideline, Journal of Clinical Oncology, 37, 10.1200/JCO.18.02096

Benboubker, 2014, Lenalidomide and Dexamethasone in Transplant-Ineligible Patients with Myeloma, New England Journal of Medicine, 371, 906, 10.1056/NEJMoa1402551

Durie, 2017, Bortezomib with lenalidomide and dexamethasone versus lenalidomide and dexamethasone alone in patients with newly diagnosed myeloma without intent for immediate autologous stem-cell transplant (SWOG S0777): a randomised, open-label, phase 3 trial, Lancet, 389, 519, 10.1016/S0140-6736(16)31594-X

O'Donnell, 2019, Updated Results of a Phase 2 Study of Modified Lenalidomide, Bortezomib, and Dexamethasone (RVd-lite) in Transplant-Ineligible Multiple Myeloma, Blood, 134, 3178, 10.1182/blood-2019-128000

Mateos, 2018, Daratumumab plus Bortezomib, Melphalan, and Prednisone for Untreated Myeloma, New England Journal of Medicine, 378, 518, 10.1056/NEJMoa1714678

Facon, 2019, Daratumumab plus Lenalidomide and Dexamethasone for Untreated Myeloma, New England Journal of Medicine, 380, 2104, 10.1056/NEJMoa1817249

Giri, 2020, Efficacy of daratumumab in the treatment of multiple myeloma with high-risk cytogenetics: Meta-analysis of randomized phase III trials, Journal of Clinical Oncology, 38, 8540, 10.1200/JCO.2020.38.15_suppl.8540

Farooqui, 2020, Daratumumab-based three drug regimens for high-risk multiple myeloma: A meta-analysis, American Society of Clinical Oncology, 38, e20549, 10.1200/JCO.2020.38.15_suppl.e20549